Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 10.8 %

Cara Therapeutics stock opened at $0.35 on Tuesday. Cara Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.31. The company has a market capitalization of $18.92 million, a P/E ratio of -0.17 and a beta of 0.68. The stock’s 50 day moving average is $0.29 and its 200 day moving average is $0.42.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, equities analysts expect that Cara Therapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC purchased a new position in Cara Therapeutics, Inc. (NASDAQ:CARA) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics at the end of the most recent reporting period. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.